Discontinued — last reported Q3 '24
CAG — Operating Income (Loss)
Idexx Laboratories CAG — Operating Income (Loss) increased by 14.7% to $277.08M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 9.4%, from $253.36M to $277.08M. Over 2 years (FY 2021 to FY 2023), CAG — Operating Income (Loss) shows an upward trend with a 10.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates improved segment-level profitability through higher sales volume, better pricing power, or enhanced operational efficiency. A decrease suggests rising costs, margin compression, or slowing demand within the veterinary diagnostic market.
Detailed definition
This metric represents the profitability of the Companion Animal Group segment after deducting operating expenses from s...
Peer comparison
Comparable to segment-level operating profit reported by other life sciences or medical device companies with distinct veterinary or diagnostic divisions.
idxx_segment_cag_operating_income_lossHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $234.74M | $201.95M | $174.13M | $223.13M | $156.53M | $221.45M | $199.84M | $261.75M | $275.51M | $253.36M | $222.12M | $279.70M | $241.55M | $277.08M |
| QoQ Change | — | -14.0% | -13.8% | +28.1% | -29.8% | +41.5% | -9.8% | +31.0% | +5.3% | -8.0% | -12.3% | +25.9% | -13.6% | +14.7% |
| YoY Change | — | — | — | — | -33.3% | +9.7% | +14.8% | +17.3% | +76.0% | +14.4% | +11.1% | +6.9% | -12.3% | +9.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Idexx Laboratories's cag — operating income (loss)?
- Idexx Laboratories (IDXX) reported cag — operating income (loss) of $277.08M in Q3 2024.
- How has Idexx Laboratories's cag — operating income (loss) changed year-over-year?
- Idexx Laboratories's cag — operating income (loss) increased by 9.4% year-over-year, from $253.36M to $277.08M.
- What is the long-term trend for Idexx Laboratories's cag — operating income (loss)?
- Over 2 years (2021 to 2023), Idexx Laboratories's cag — operating income (loss) has grown at a 10.9% compound annual growth rate (CAGR), from $824.02M to $1.01B.
- What does cag — operating income (loss) mean?
- The profit earned by the Companion Animal Group segment from its core business operations.